Vitamin B12 Deficiency in Resistant Schizophrenia in Tropics

Thirunavukarasu Kumanan1*, Naveen Thomas2, Selladurai Pirasath1

1University Medical Unit, Teaching hospital, Jaffna, Sri Lanka
2The Royal Melbourne Hospital & North Western Mental Health, Melbourne, Australia

Email: *mtkumanan@yahoo.com

Abstract

Vitamin B12 deficiency and hyperhomocysteinemia are common in tropical developing countries. In prevalence study, among Indian population by Yajnik and colleagues, 67% of men had low vitamin B12 concentration and 58% had hyperhomocysteinemia [1]. Here, we report two patients with vitamin B12 deficiency presented with symptoms of schizophrenia and required very high doses of antipsychotic medication surprisingly without any anticipated extra pyramidal side effects. The initial requirement of high dose of antipsychotic medication significantly came down after adding parenteral cobalamin supplementation.

1. Introduction

Vitamin B12 deficiency and hyperhomocysteinemia play important role in resistant schizophrenia. Low serum B12 level has been reported in resistant schizophrenia in literature [1]. Vitamin supplementation could provide therapeutic benefits through separate mechanisms of action than current medication regimens, which focus largely on monoamine and histamine signalling. The research indicates that taken in high doses, B vitamins—such as B-6, B-8, and B-12—can significantly reduce schizophrenia symptoms. Additionally, a combined dose of several vitamins was shown to have the same beneficial effect. However, low doses of the vitamins were revealed to be ineffective.
2. Case I

A 24 year old male, presented with an 8 month history suggestive of schizophrenia with normal cognitive and neurological functions. He was started on oral risperidone and the dose was gradually increased to 12 mg/day, due to poor response to treatment however no extra pyramidal side effects were noted. As the MCV was 98.4 [75 - 96 fl] he was evaluated for B₁₂ and folic acid deficiency. Serum B₁₂ was 159.5 pg/ml (normal range: 220 - 900 pg/ml), folic acid was 4.08 ng/ml (normal range: 3 - 17 ng/ml) and homocysteine was 58.5 μM/L (normal range: 4.3 - 9.9 μM/L), confirming the possibility of vitamin B₁₂ deficiency. Renal and hepatic indices were normal. Mr. A was started on a course of intramuscular vitamin B₁₂ injections. After two months of treatment he developed extrapyramidal side effects and the dose of risperidone was reduced gradually to 6 mg daily without any worsening of psychotic symptoms. His homocysteine level has come down to normal limit at that time. He remained asymptomatic and was functioning well at 6 months follow up.

3. Case II

Mr. B, a 28 year old male, presented with a 2 year history suggestive of schizophrenia and his symptoms were uncontrolled over the preceding six months. At presentation he was on high doses of two typical antipsychotics (chlorpromazine and trifluoperazine) equivalent to 1400 mg daily dose of chlorpromazine with no manifestations of extrapyramidal symptoms. On examination, he had pallor, glossitis and angular stomatitis with normal cognitive and neurological functions. Mr. B was evaluated for B₁₂ deficiency; his MCV was 112 [75 - 96 fl], serum B₁₂ was 119 pg/ml (normal range: 220 - 900 pg/ml), folic acid was 4.5 ng/ml (normal range: 3 - 17 ng/ml) and homocysteine was 49.5 μM/L (normal range: 4.3 - 9.9 μM/L). These results confirmed vitamin B₁₂ deficiency. Serum electrolytes, renal and hepatic indices were normal. After a month of treatment with intramuscular vitamin B₁₂ therapy, Mr. B developed severe extrapyramidal side effects and hence trifluoperazine was withheld and he was maintained on chlorpromazine 600 mg daily. His homocysteine and B₁₂ levels were normalized after a month of treatment. Parenteral B₁₂ administration was continued monthly. He remained asymptomatic and was functioning well at 3 months follow up.

4. Discussion

The role of one carbon metabolism in neuropsychiatric disorders is reviewed by Smythies et al. and Cohen et al. [2] [3]. While there are many reports of schizophrenia being associated with vitamin B₁₂ deficiency, we would like to highlight two issues relevant to the above mentioned case scenarios [4].

1) Need for high dose antipsychotic therapy in the acute phase of treatment and lack of extrapyramidal side effects in this group of patients.

2) Evaluation for B₁₂ and folate deficiency should be included in the assessment for treatment resistant psychosis.
When a person has B₁₂ deficiency there is a possibility of dopamine accumulation which makes the psychosis resistant to antipsychotic therapy, and the patient may not develop extrapyramidal side effects and this can be reversed by vitamin B₁₂ supplementation. Previous surveys have shown that a small but substantial number of psychiatric patients ranging from 6% - 15% have low serum B₁₂ levels [5].

The methyl group of essential amino acid Methionine is activated by converting it to S-Adenosyl Methionine (SAM) by Adenosine Triphosphate (ATP) and Ethionine Adenosyl Transferase and SAM is the sole methyl donor in the central nervous system. S-Adenosyl Homocysteine (SAH), demethylation product of SAM is hydrolysed to Homocysteine (Hcy) in a reversible reaction. In the majority of tissues, Hcy is remethylated to Methionine by the Vitamin B₁₂-dependent enzyme Methionine Synthase (MS) (Figure 1). In Vitamin B₁₂ or folic acid deficiency states this remethylation will be reduced, which in turn reduce the synthesis of SAM and results in decreased synthesis of Noradrenaline or accumulation of Dopamine [6].

In developing countries, underlying B₁₂ deficiency should be considered in all the patients who are not responding to antipsychotic medications and before labelling them as treatment resistance or commencing on 2nd line therapies like clozapine. It is advisable to do B₁₂ level during the initial evaluation because psychosis can precede anaemia. Homocystine assay is also to be considered in selected cases [7] in a view of early initiation of cobalamin supplementation.

Vitamin B₁₂ deficiency and hyperhomocysteinemia was an etiological factor in our cases. Vitamin B₁₂ therapy had a significant outcome in our cases. Low serum B₁₂ levels have been reported in resistant schizophrenia [1] and Vitamin B₁₂ therapy had good outcome in literature [5].

The informed consent was obtained from the patients to report this case in this journal.

---

**Figure 1.** Role of vitamin B₁₂ in homocysteine metabolic pathway.
References


Submit or recommend next manuscript to OALib Journal and we will provide best service for you:

- Publication frequency: Monthly
- 9 subject areas of science, technology and medicine
- Fair and rigorous peer-review system
- Fast publication process
- Article promotion in various social networking sites (LinkedIn, Facebook, Twitter, etc.)
- Maximum dissemination of your research work

Submit Your Paper Online: [Click Here to Submit](#)
Or Contact [service@oalib.com](mailto:service@oalib.com)